

# Creo Medical

## FY25 results validate growth strategy

Creo Medical has reported its headline **FY25 results**, delivering fully on its guided revenue and cost savings targets for the year. Core revenues were reported at £6.0m, 50% y-o-y growth and within the 40–60% growth guidance. Notably, the sales uptick was driven by both an increase in new users and improved utilisation from existing users, which we view as a positive leading indicator for product adoption and future revenue scalability. Operating expenses fell by 20% to £18.4m, fully achieving the targeted £5m cost savings for the year. Underlying operating loss narrowed by >40% y-o-y to £13.3m, outperforming our forecast of £14.1m. Creo ended FY25 with a gross cash balance of £12.4m, broadly in line with our estimate of £12.7m. Looking ahead, we estimate that a broadly similar revenue growth trajectory will be required in FY26–28 for Creo to achieve EBITDA break even in FY28. The company retains the right to monetise the remaining 49% stake it holds in Creo Medical Europe (CME), which should provide significant downside protection if required. We will present our updated estimates in a more detailed update note shortly.

Year end	Revenue (£m)	PBT (£m)	EPS (p)	P/E (x)	Yield (%)
12/23	4.0	(25.0)	(0.07)	N/A	N/A
12/24	4.0	(27.7)	(0.07)	N/A	N/A
12/25e	6.0	(14.8)	(0.04)	N/A	N/A

Note: The FY25 revenue figure is as reported. PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

In its first full year after the announcement of the strategic restructuring in H224, Creo delivered a strong operating performance in FY25, marked by accelerated revenue growth and materially improved cost discipline. Revenues increased by 50% y-o-y to £6.0m, in line with our estimates and market expectations, with momentum building towards H2 when revenues rose 58% y-o-y to £3.8m (H224: £2.4m). This topline growth was driven by continued clinical adoption from new users and higher utilisation from existing customers across Creo's core product portfolio, a positive indicator of market reception and uptake of the company's core electrosurgical products. At the same time, underlying operating costs fell 20% to £18.4m, reflecting results from restructuring actions taken in H224 and tighter cost control, leading to a c 40% reduction in underlying operating loss to £13.3m. This was ahead of our estimate of a £14.1m operating loss.

Notably, Creo reported encouraging traction across both resection and ablation franchises. Speedboat Notch saw increased use in advanced gastrointestinal procedures, including per-oral endoscopic myotomies, following launch in April 2025, and SpydrBlade Flex received positive early market feedback following its US, UK and EU launches during the year. The ablation device MicroBlate Flex (which is being developed to work with Intuitive Surgical's ION robots) commenced first commercial sales from initial clinical sites after the first 20 patients had been treated, while MicroBlate Fine saw a limited release in research sites in Europe, Asia-Pacific and the US, which should support data generation in pancreas and liver indications.

Creo ended FY25 with a gross cash balance of £12.4m and we believe it is on track to deliver EBITDA break even in FY28, should the sales momentum continue. Creo still holds the optionality to monetise the remaining 49% stake it has in CME. For context, the majority 51% stake was divested in Q324 for net proceeds of €30m.


## FY25 trading update

Healthcare

21 January 2026

<b>Price</b>	<b>12.25p</b>
<b>Market cap</b>	<b>£51m</b>
Gross cash/(debt) as at end-	£12.4m
December 2025	
Shares in issue	412.5m
Code	CREO
Primary exchange	AIM
Secondary exchange	N/A

### Share price performance



### Business description

Creo Medical is a UK-based healthcare company focused on the development and commercialisation of minimally invasive electrosurgical devices. It has six products in the flagship CROMA platform, all of which have been CE marked and cleared by the FDA. Licensing opportunities for its Kamaptive IP (current partnerships with major robotics players Intuitive Surgical and CMR Surgical) offer further monetisation opportunities. In February 2025, Creo completed the divestment of a 51% stake in its consumables business to Chinese market leader Micro-Tech.

### Analysts

Jyoti Prakash, CFA	+44 (0)20 3077 5700
Arron Aatkar, PhD	+44 (0)20 3077 5700

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

[Edison profile page](#)

**Creo Medical is a research client of Edison Investment Research Limited**

---

## General disclaimer and copyright

This report has been commissioned by Creo Medical and prepared and issued by Edison, in consideration of a fee payable by Creo Medical. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

**Accuracy of content:** All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

**Exclusion of Liability:** To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

**No personalised advice:** The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

**Investment in securities mentioned:** Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2026 Edison Investment Research Limited (Edison).

---

## Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

---

## New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

---

## United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

---

## United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.